Your browser doesn't support javascript.
Performance evaluation of antibody-based point-of-care devices intended for the identification of immune responses to SARS-CoV-2.
Furuya, Andrea K M; Wagner, Christine; Connors, Julia; Bodnar, Janine; Miller, Thomas; Ryman, Nko Lea; Warszycki, Casey J; Wong, Susan J; Walsh, Anne C; McDonough, Kathleen A; Lee, William T.
  • Furuya AKM; The Wadsworth Center, New York State Department of Health, Albany, NY, USA. Electronic address: andrea.furuya@health.ny.gov.
  • Wagner C; The Wadsworth Center, New York State Department of Health, Albany, NY, USA.
  • Connors J; The Wadsworth Center, New York State Department of Health, Albany, NY, USA.
  • Bodnar J; The Wadsworth Center, New York State Department of Health, Albany, NY, USA.
  • Miller T; The Wadsworth Center, New York State Department of Health, Albany, NY, USA.
  • Ryman NL; The Wadsworth Center, New York State Department of Health, Albany, NY, USA.
  • Warszycki CJ; The Wadsworth Center, New York State Department of Health, Albany, NY, USA.
  • Wong SJ; The Wadsworth Center, New York State Department of Health, Albany, NY, USA.
  • Walsh AC; The Wadsworth Center, New York State Department of Health, Albany, NY, USA.
  • McDonough KA; The Wadsworth Center, New York State Department of Health, Albany, NY, USA; Department of Biomedical Sciences, The School of Public Health, The University at Albany, Albany, NY, USA.
  • Lee WT; The Wadsworth Center, New York State Department of Health, Albany, NY, USA; Department of Biomedical Sciences, The School of Public Health, The University at Albany, Albany, NY, USA. Electronic address: william.lee@health.ny.gov.
Diagn Microbiol Infect Dis ; 99(4): 115298, 2021 Apr.
Article in English | MEDLINE | ID: covidwho-987459
ABSTRACT
The novel coronavirus outbreak caused by the severe acute respiratory syndrome coronavirus (SARS-CoV-2) was first identified in December of 2019 in Wuhan, China. The local outbreak quickly rose to pandemic level that has spread to more than 188 countries with more than 19 million cases and 732,467 deaths worldwide. The current recommendation for testing is RT-PCR based tests of nasopharyngeal or alternatively nasal- and/or oropharyngeal swabs that detects infection with SARS-CoV-2 to diagnose acute infection. However, there is an urgent need for a quick and accurate antibody-based point-of-care test method to quickly identify evidence of SARS-CoV-2 infection among people who might be missed through active case finding and surveillance efforts. Serology tests measure the presence of antibodies in serum after infection. Here we compared the performance characteristics of 6 commercially available antibody-based point-of-care devices and their potential for identification of individuals infected at some time by SARS-CoV-2.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulin G / Immunoglobulin M / COVID-19 Serological Testing / COVID-19 / Antibodies, Viral Type of study: Diagnostic study / Experimental Studies Limits: Humans Language: English Journal: Diagn Microbiol Infect Dis Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulin G / Immunoglobulin M / COVID-19 Serological Testing / COVID-19 / Antibodies, Viral Type of study: Diagnostic study / Experimental Studies Limits: Humans Language: English Journal: Diagn Microbiol Infect Dis Year: 2021 Document Type: Article